Floatz logo

Carboplatin

HR+ Breast Cancer

Avenzo Therapeutics, Inc.Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the HR+ Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Ribociclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →